INNOVATE (VATE) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Executive summary
The 2026 Annual Meeting will be held virtually on June 11, 2026, with voting available online, by phone, or by mail.
Key business highlights include refinancing transactions, revenue growth in DBM Global, regulatory milestones in Pansend Life Sciences, and expansion in Broadcasting.
The company emphasizes active stockholder engagement and transparency, with ongoing dialogue on executive compensation, governance, and ESG matters.
Voting matters and shareholder proposals
Four proposals will be voted on: election of four directors, advisory say-on-pay vote, amendment to increase shares in the equity award plan, and ratification of BDO USA, P.C. as auditor.
The Board recommends voting FOR all proposals and nominees.
Only stockholders of record as of April 22, 2026, are entitled to vote.
Board of directors and corporate governance
The Board consists of four independent directors, all nominated for re-election, with diverse backgrounds in business, finance, and public policy.
Three standing committees: Audit, Compensation, and Nominating & Governance, all composed of independent directors.
The company separates the roles of Chairman and CEO and encourages director education and stockholder communications.
Corporate governance guidelines address director qualifications, independence, and succession planning.
Latest events from INNOVATE
- Annual meeting to vote on directors, compensation, equity plan, and auditor ratification.VATE
Proxy filing28 Apr 2026 - Q4 2025 revenue up 61.7% to $382.7M, with strong Infrastructure growth and narrowing net loss.VATE
Q4 202526 Mar 2026 - Q2 net income rose to $14.4M as margins improved and Life Sciences posted record sales.VATE
Q2 20242 Feb 2026 - Q3 revenue dropped 35.5% to $242.2M; growth in Life Sciences and Spectrum, but going concern risk remains.VATE
Q3 202416 Jan 2026 - Revenue declined, but Life Sciences and Spectrum grew; debt reduced and backlog remains strong.VATE
Q4 202425 Dec 2025 - Annual meeting to vote on directors, executive pay, auditor, and governance after major 2024 changes.VATE
Proxy Filing2 Dec 2025 - Director elections, say-on-pay, and auditor ratification up for vote at June 2025 meeting.VATE
Proxy Filing2 Dec 2025 - Annual meeting adjourned for technical reasons; voting postponed to June 18, 2024.VATE
Proxy Filing2 Dec 2025 - Revenue fell 22.7% to $242M, net loss $22M, Life Sciences grew, major debt refinancing completed.VATE
Q2 202523 Nov 2025